155
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
31
Burton AW, Driver LC, Mendoza TR, Syed G. Oral transmucosal fentanyl citrate in the
outpatient management of severe cancer pain crises: a retrospective case series. Clini-
cal Journal of Pain 2004; 20: 195-197.
32
Burton AW, Reddy SK, Shah HN, Tremont-Lukats I, Mendel E. Percutaneous vertebro-
plasty – a technique to treat refractory spinal pain in the setting of advanced metastatic
cancer: a case series. Journal of Pain and Symptom Management 2005; 30: 87-95.
33
Burton B, Zeppetella G. Assessing the impact of breakthrough cancer pain. Br J Nurs
2011; 20(10): S14, S16-19.
34
Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Atwell TD, Farrell MA, Welch TJ,
Maus TP. Image-guided ablation of painful metastatic bone tumors: a new and effective
approach to a difficult problem. Skeletal Radiology 2006; 35: 1-15.
35
Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Conno F. Pain
measurement tools and methods in clinical research in palliative care: recommen-
dations of an Expert Working Group of the European Association of Palliative Care.
Journal of Pain and Symptom Management 2002; 23: 239-255.
36
Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, Jackson KA, Lickiss
N, Muirden N, Pisasale M, Moulin D, Schulz VN, Rico Pazo MA, Serrano JA, Andersen H,
Henriksen HT, Mejholm I, Sjogren P, Heiskanen T, Kalso E, Pere P, Poyhia R, Vuorinen E,
Tigerstedt I, Ruismaki P, Bertolino M, Larue F, Ranchere JY, Hege-Scheuing G, Bowdler I,
Helbing F, Kostner E, Radbruch L, Kastrinaki K, Shah S, Vijayaram S, Sharma KS, Devi PS,
Jain PN, Ramamani PV, Beny A, Brunelli C, Maltoni M, Mercadante S, Plancarte R, Schug
S, Engstrand P, Ovalle AF, Wang X, Alves MF, Abrunhosa MR, Sun WZ, Zhang L, Gazizov
A, Vaisman M, Rudoy S, Gomez Sancho M, Vila P, Trelis J, Chaudakshetrin P, Koh ML,
Van Dongen RT, Vielvoye-Kerkmeer A, Boswell MV, Elliott T, Hargus E, Lutz L; Working
Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and
syndromes in patients with cancer pain. An international survey. Palliative Medicine
2004; 18(3): 177-183.
37
Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and
syndromes. Pain 1999; 82(3): 263-274.
38
Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennan L, et al. Safety and
efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with
chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain
2004; 108: 17-27.
39
Casuccio A, Mercadante S, Fulfaro F. Treatment strategies for cancer patients with
breakthrough pain. Expert Opin Pharmacother 2009; 10(6): 947-953.
40
Christelis N, Filshie J. Other therapeutic interventions. In: Davies A (Hrsg.), Cancer-rela-
ted breakthrough pain. Oxford: Oxford University Press; 2006, 97-110.
41
Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, et al. Dose-
titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of
breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
Journal of Clinical Oncology 1998; 16: 3238-3245.
Literaturverzeichnis